Evogene Ltd. (EVGN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
Analysis Summary
Evogene Ltd. reported revenue of $3.9M in the most recent fiscal year, growing at a 5-year CAGR of 29.9%.
Trailing-twelve-month margins: gross margin -14.2%, operating margin -10.2%, net margin -7.0%.
At the current price of $0.50, EVGN has negative trailing earnings (P/E not meaningful) and an ROE of 7.66%. Market capitalisation stands at $4M.
Balance sheet quality for EVGN: current ratio of 4.5, net cash position of $10.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | -1.98 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 766.01% |
| Return on Invested Capital | -121.41% |
| Return on Assets | -68.20% |
| Gross Margin | -14.16% |
| Operating Margin | -1020.35% |
| Net Margin | -696.26% |
Financial Health
| Debt / Equity | -0.64 |
| Current Ratio | 3.57 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -20.48 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EVGN | Evogene Ltd. | $4M | 7.7% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -14.90% |
| 3 months | -5.58% |
| Year-to-date | -54.93% |
| 1 year | -59.02% |
| 3 years | -92.62% |
| 5 years | -98.37% |
52-Week Range
| 52-week High | $1.50 |
| 52-week Low | $0.37 |
| Avg Volume (90d) | 1.4M |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explore sector: Healthcare · Biotechnology
More sections of EVGN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks